ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      60,232.18
      1.68%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Galapagos (GLPG)

      7. Galapagos (GLPG) News

      GLPG

      Galapagos (GLPG)

      Galapagos
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:GLPG
      DateTimeSourceHeadlineSymbolCompany
      03/01/20164:09PMGlobeNewswire Inc.Galapagos receives transparency notification from Johnson & JohnsonEU:GLPGGalapagos
      02/16/20164:17PMGlobeNewswire Inc.Galapagos starts SAPHIRA Phase 2 study with GLPG1837 in cystic fibrosis patientsEU:GLPGGalapagos
      02/01/20164:40PMGlobeNewswire Inc.Galapagos receives transparency notification from Wellington Management Group LLPEU:GLPGGalapagos
      01/26/20161:35AMGlobeNewswire Inc.Galapagos reports results with GLPG1205 in ulcerative colitisEU:GLPGGalapagos
      01/25/20161:37AMGlobeNewswire Inc.Transparency notification - Gilead Sciences, Inc. holds 14.75% of Galapagos sharesEU:GLPGGalapagos
      01/19/20165:02PMGlobeNewswire Inc.Galapagos and Gilead complete closing of their global collaboration for filgotinibEU:GLPGGalapagos
      01/19/20161:37AMGlobeNewswire Inc.Galapagos advances CF clinical developmentEU:GLPGGalapagos
      01/13/20161:53AMGlobeNewswire Inc.Galapagos and Gilead cleared by US FTC to close their global partnership on filgotinibEU:GLPGGalapagos
      12/22/20154:07PMGlobeNewswire Inc.Galapagos receives transparency notification from Wellington Management Group LLPEU:GLPGGalapagos
      12/22/20154:03PMGlobeNewswire Inc.Galapagos creates new warrant plansEU:GLPGGalapagos
      12/17/20157:19AMDow Jones NewsGalapagos, Gilead Partner to Develop FilgotinibEU:GLPGGalapagos
      12/17/20151:10AMGlobeNewswire Inc.GALAPAGOS AND GILEAD ANNOUNCE GLOBAL PARTNERSHIP TO DEVELOP FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER IN...EU:GLPGGalapagos
      12/07/20154:52PMGlobeNewswire Inc.Filgotinib meets primary endpoint in phase 2 study in patients with moderate to severe Crohn's diseaseEU:GLPGGalapagos
      12/04/20154:04PMGlobeNewswire Inc.Galapagos increases share capital through warrant exercisesEU:GLPGGalapagos
      11/21/20157:27AMGlobeNewswire Inc.Invitation to the Special Shareholders' Meeting of Galapagos on 22 December 2015EU:GLPGGalapagos
      11/20/20151:40AMGlobeNewswire Inc.Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives EU3.5 million milestone from ServierEU:GLPGGalapagos
      11/12/20154:12PMGlobeNewswire Inc.Galapagos reports third quarter 2015 cash position of EU374 MEU:GLPGGalapagos
      11/08/20154:08AMGlobeNewswire Inc.Galapagos builds on strong profile of filgotinib in 7 presentations at ACR 2015EU:GLPGGalapagos
      11/04/20151:36AMGlobeNewswire Inc.Dr. Christine Mummery appointed to Galapagos' Board of DirectorsEU:GLPGGalapagos
      10/15/20151:44AMGlobeNewswire Inc.Galapagos advances triple combination therapy in cystic fibrosisEU:GLPGGalapagos
      10/09/20151:39AMGlobeNewswire Inc.Positive safety and tolerability for novel potentiator GLPG1837EU:GLPGGalapagos
      10/08/20151:37AMGlobeNewswire Inc.Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015EU:GLPGGalapagos
      10/02/20154:16PMGlobeNewswire Inc.Galapagos raises EU1.2 million through warrant exercisesEU:GLPGGalapagos
      09/25/20156:06PMDow Jones NewsADR Shares End Mixed; Galapagos, Abengoa Trade ActivelyEU:GLPGGalapagos
      09/25/201510:48AMGlobeNewswire Inc.Galapagos to advance filgotinib to Phase 3 in rheumatoid arthritisEU:GLPGGalapagos
      09/22/20151:37AMGlobeNewswire Inc.Galapagos presents promising pre-clinical and Phase 1 results with autotaxin inhibitor GLPG1690 at ERSEU:GLPGGalapagos
      05/26/20154:06PMGlobeNewswire Inc.Galapagos receives transparency notificationsEU:GLPGGalapagos
      05/19/20154:12PMGlobeNewswire Inc.Galapagos announces capital increaseEU:GLPGGalapagos
      05/19/20154:07PMGlobeNewswire Inc.Galapagos announces closing of NASDAQ IPOEU:GLPGGalapagos
      05/18/20151:36AMGlobeNewswire Inc.Galapagos announces full exercise of underwriters' option to purchase additional sharesEU:GLPGGalapagos
       Showing the most relevant articles for your search:EU:GLPG